ScreenerHero

MTRI Mentari Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · mentaritx.com
18.60USD+1.36%Mkt Cap: 1.08B USDP/E: —

Mentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention. The company's products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous …

Industry Peers

Biotechnology
Screen all Biotechnology
VRTX
Vertex Pharmaceuticals Incorporated
$136.56BUSDP/E 34.7
REGN
Regeneron Pharmaceuticals, Inc.
$98.84BUSDP/E 21.1
MRNA
Moderna, Inc.
$90.38BUSD
CSL
CSL Limited
$66.07BUSD
UCB
UCB SA
$62.48BUSDP/E 26.2
ARGX
argenx SE
$61.05BUSDP/E 35.3
ARGX
argenx SE
$60.37BUSDP/E 33.3
ONC
BeOne Medicines AG
$47.58BUSDP/E 53.4
RPRX
Royalty Pharma plc
$39.85BUSDP/E 45.3
RVMD
Revolution Medicines, Inc.
$37.27BUSD
GMAB
Genmab A/S
$31.67BUSDP/E 43.9
GMAB
Genmab A/S
$31.43BUSDP/E 45.8
ROIV
Roivant Sciences Ltd.
$28.64BUSD
INSM
Insmed Incorporated
$26.58BUSD
INCY
Incyte Corporation
$24.66BUSDP/E 61.7
ALNY
Alnylam Pharmaceuticals, Inc.
$22.11BUSDP/E 8.3
BNTX
BioNTech SE
$21.22BUSD
ASND
Ascendis Pharma A/S
$18.12BUSDP/E 18.1
EXEL
Exelixis, Inc.
$16.84BUSDP/E 20.7
JAZZ
Jazz Pharmaceuticals plc
$15.50BUSDP/E 71.5
Insiders, last 90 days6 buys

Key Statistics

Company
Market Cap1.08B USD
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)—
Revenue/Share—
Last Price18.60 USD
Fiscal Year End—
MR Quarter—
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B—
EPS (TTM)—
EPS (Forward)—
52W Range
12.2082% of range20.00
52W High20.00 USD
52W Low12.20 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE—
ROA—
ROIC—
ROCE—
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF—
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Net Debt/FCF—
Balance Sheet
Debt/Equity—
Current Ratio—
Quick Ratio—
Book Value/Sh—
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateNov 5, 2026
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.58.30M
Float—
Insiders0.00%
Institutions0.56%
Technical
SMA 5014.12 (+31.8%)
SMA 20012.24 (+52.0%)
Beta—
S&P 52W Chg12.75%
Avg Vol (30d)65.62K
Avg Vol (10d)42.41K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—

About Mentari Therapeutics (NASDAQ: MTRI)

›

Mentari Therapeutics (NASDAQ: MTRI) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector.

The shares were at 18.60 USD on 13 November 2026. Its 52-week range is 12.20 USD to 20.00 USD: the price is 7.0% below the high and 52.5% above the low.

Its market capitalisation is 1.08B USD.

Mentari Therapeutics reports an operating margin of 0.0%.

The next earnings report is expected on 10 February 2027.

Compare MTRI with VRTX and REGN →